Estrella Immunopharma, Inc. (ESLAW)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Peers in Healthcare
Estrella Immunopharma, Inc. has no peer companies in this window.
Recent press releases
Estrella Immunopharma, Inc. has not issued a press release in this window.
SEC filings
All filings →Estrella Immunopharma, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Estrella Immunopharma, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Estrella Immunopharma, Inc.
All people →No officers or directors have been indexed for Estrella Immunopharma, Inc..